FDA Accepts Alvotech’s AVT16 – A New Interchangeable Biosimilar to Entyvio
Alvotech’s AVT16 biosimilar to Entyvio is under FDA review, aiming for cheaper, interchangeable treatment for gut diseases.
/ 242 items
#XY Event-Driven Stocks↓
Johnson & Johnson Acquires Firefly Bio for $1B to Unlock New Cancer Treatments
The deal brings Firefly’s Firelink platform that precisely targets hard-to-treat KRAS-driven tumors while sparing healthy tissue.
Nurix and Roche Team Up in Massive $2.3B Partnership for Next-Gen Blood Cancer Treatment
Nurix Therapeutics gets $700M upfront in a potential $2.3B partnership with Roche to co-develop bexobrutideg, a next-gen oral BTK degrader for CLL, MS, and immunology.
Tango Therapeutics Achieves 92% Response Rate in Hard-to-Treat Pancreatic Cancer
Tango drug combo shows 92% response in advanced pancreatic cancer, with strong early results and good safety in trials.
Incyte Buys Vega Therapeutics for Up to $2 Billion to Bring New Once-a-Month Shot for Bleeding Disorder
Incyte is buying Vega Therapeutics to add VGA039 — a new once-monthly under-the-skin injection for von Willebrand disease (VWD).
Cullinan’s CLN-978 Shows Deep B-Cell Depletion and Remissions in Lupus and RA
Cullinan Therapeutics’ CLN-978 T-cell engager showed deep B-cell depletion and clinical remissions in hard-to-treat lupus and rheumatoid arthritis patients after a single dose at EULAR 2026.